Natera, Inc. (NTRA)

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today shared the results from two oral presentations that were presented at the American Society of Hematology (ASH) Annual Meeting. Real-world Signatera Analysis: Oral Presentation on December 6 A real-world analysis of personalized circulating tumor DNA (ctDNA) detection in lymphoma evaluated 144 patients across 14 lymphoma subtypes, including aggressive and indolent lymphomas.

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) stock is trading lower on Friday, despite no company-specific news, likely reacting to Natera Inc.'s (NASDAQ: NTRA) acquisition of cancer diagnostics firm Foresight Diagnostics for $275 million upfront and up to $175 million in additional earnouts tied to revenue- and reimbursement-based milestones.

AUSTIN, Texas & BOULDER, Colo.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, today announced that Natera has completed a transaction to acquire Foresight. Foresight is a cancer diagnostics company and CLIA-registered laboratory. The company's circulating tumor DNA (ctDNA)-based MRD tests leverage its patented PhasED-Seq™ technology, targetin.

Edgestream Partners L.P. lifted its position in Natera, Inc. (NASDAQ: NTRA) by 154.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,316 shares of the medical research company's stock after acquiring an additional 12,925 shares during the period. Edgestream

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced that new data on Signatera will be presented at the 2025 American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, Florida. Natera and its collaborators will present four abstracts highlighting the clinical validity and utility of Signatera in hematologic malignancies. The datasets include an oral presentation on a retrospective.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that at least twelve abstracts highlighting Signatera will be shared at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place December 9-12. The presentations encompass aggregated data from more than 50,000 patients in real-world evidence and prospective clinical studies, demonstrating the prognostic and predictive power of Signatera across diverse b.

Druckenmiller invests his personal and family's wealth through his fund, the Duquesne Family Office. Druckenmiller is high on biotech stocks, with his top three holdings at the end of the third quarter all in the sector.

Coldstream Capital Management Inc. increased its holdings in Natera, Inc. (NASDAQ: NTRA) by 17.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,849 shares of the medical research company's stock after purchasing an additional 427 shares during the

Creative Planning increased its holdings in shares of Natera, Inc. (NASDAQ: NTRA) by 29.2% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,146 shares of the medical research company's stock after purchasing an additional 2,521 shares

Stanley Druckenmiller has been one of the most successful investors, a billionaire with a long record of high returns in global macro investing.

Natera, Inc. ( NTRA ) 7th Annual Wolfe Research Healthcare Conference November 19, 2025 10:00 AM EST Company Participants Mike Brophy - Chief Financial Officer Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Presentation Douglas Schenkel Wolfe Research, LLC All right. So last run of the day.

Natera, Inc. ( NTRA ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:00 AM EST Company Participants Steve Chapman - CEO & Director Mike Brophy - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division So I am going to go ahead and kick it off. I'm Tycho Peterson from the Jefferies Life Science team.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its employees contributed more than 1,500 volunteer hours during the company's fourth annual Volunteer Month. This initiative takes place each October and is organized by Natera Nurtures, the company's employee resource group dedicated to community service and philanthropy. Natera encourages employees to live one of its core values, Be Ready to Change the Wo.

Insights into Stanley Druckenmiller (Trades, Portfolio)'s Third Quarter 2025 Portfolio Adjustments Stanley Druckenmiller (Trades, Portfolio) recently submitted

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point-of-care solutions in oncology, today announced the integration of Natera's oncology testing portfolio into OncoEMR®, Flatiron's cloud-based Electronic Medical Record (EMR) platform. The integration enables seamless electronic ordering and results delivery for Natera's oncology tes.

Natera, Inc. ( NTRA ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - CEO & Director Solomon Moshkevich - President of Clinical Diagnostics Alexey Aleshin - GM of Oncology and ECD & Chief Medical Officer Conference Call Participants Noah Kava - Jefferies LLC, Research Division Douglas Schenkel - Wolfe Research, LLC Daniel Brennan - TD Cowen, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Casey Woodring - JPMorgan Chase & Co, Research Division Puneet Souda - Leerink Partners LLC, Research Division Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Presentation Operator Welcome to Natera's 2025 Third Quarter Financial Results Conference Call.